hVIVO plc (AIM & Euronext: HVO), a rapidly expanding specialist contract research organisation (CRO) renowned for its expertise in human challenge clinical trials for infectious and respiratory diseases, has announced its latest engagement in a significant Phase 2b field study. The study will assess an influenza drug candidate, marking a milestone as hVIVO’s largest field […]
In a strategic move to bolster its position in the pharmaceutical research sector, Charles River Laboratories International, Inc. has agreed to acquire Michigan-based non-clinical contract research organization (CRO), MPI Research, for approximately $800 million. This acquisition is set to enhance Charles River’s capabilities in early-stage drug development and expand its service offerings across the biopharma […]
